US FDA Considering Opioid Mail-Back Envelope Mandate, But Industry Has Heard This Before

 
• By Derrick Gingery
  
drug mailed in envelope
The FDA described two potential options for mandating pre-paid mail-back envelopes under the opioid REMS in a Federal Register notice. • Source: Shutterstock

More from Drug Safety

More from Pink Sheet